You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
疫苗之王艾美疫苗通過港交所上市聆訊
格隆匯 09-20 10:51
格隆匯9月20日丨港交所文件顯示,國內最大的全產業鏈民營疫苗公司艾美疫苗通過港交所上市聆訊,擬在港交所主板掛牌上市。招股書顯示,按2021年批簽發量(不包括COVID-19疫苗)計,艾美疫苗是中國第二大疫苗公司,所佔市場份額為7.4%,僅次於國有企業中國醫藥集團中國生物技術股份有限公司。根據灼識諮詢的資料,艾美疫苗是唯一一家在全球範圍內擁有全部五種經過驗證的人用疫苗平台技術的中國疫苗企業,所擁有的平台技術包括細菌疫苗平台技術、病毒疫苗平台技術、基因工程疫苗平台技術、聯合疫苗平台技術及mRNA疫苗平台技術,且每種平台均有至少一款獲批產品或處於臨牀階段或臨牀申請階段的在研疫苗。公司在研mRNACOVID-19疫苗已進入臨牀III期,是唯二兩家進入III期臨牀試驗階段的公司之一,研發進度行業領先。在研的重磅創新疫苗PCV13也已進入III期臨牀。公司目前已商業化8款針對6個疾病領域的疫苗產品,包括狂犬病、乙型肝炎、甲型肝炎等,其中,乙型肝炎疫苗及人用狂犬病疫苗為公司在市場上處於領先地位的主要商業化疫苗產品。招股書顯示,2019年至2021年,公司總收入分別為9.516億元、16.380億元、15.701億元。同期公司的毛利分別為7.328億元、13.541億元、12.947億元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account